M&A Deal Summary

Evolva Acquires Allylix

On December 16, 2014, Evolva acquired chemicals company Allylix for 46M USD

Acquisition Highlights
  • This is Evolva’s 1st transaction in the Chemicals sector.
  • This is Evolva’s largest (disclosed) transaction.
  • This is Evolva’s 1st transaction in the United States.
  • This is Evolva’s 1st transaction in California.

M&A Deal Summary
Date 2014-12-16
Target Allylix
Sector Chemicals
Buyer(s) Evolva
Deal Type Add-on Acquisition
Deal Value 46M USD

Target

Allylix

San Diego, California, United States
Allylix, Inc. is a renewable chemicals company that develops terpene products and their derivatives for the flavor and fragrance, food ingredient, pharmaceutical, agricultural and biofuel markets.

Search 199,712 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Evolva

Reinach, Switzerland
Category Company
Founded 2004
Sector Life Science
Employees65
Revenue 16M CHF (2022)
DESCRIPTION

Evolva is a provider of biosynthetic and evolutionary technologies to create and optimize small molecule compounds and their production routes. Evolva Holding was incorporated in 2004 and is based in Reinach, Switzerland.

DEAL STATS #
Overall 2 of 2
Sector (Chemicals) 1 of 1
Type (Add-on Acquisition) 2 of 2
State (California) 1 of 1
Country (United States) 1 of 1
Year (2014) 2 of 2
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-07-31 Prosarix

Cambridge, United Kingdom

Prosarix Ltd. is a biotechnology company. Prosarix develops computational products for the biotech and pharmaceutical sectors.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-12-17 Evolva Holding - EV-035

Switzerland

EV-035 is a series of novel small molecule broad spectrum antibiotics of the 4-oxoquinolizine class and targets bacterial type IIa topoisomerase.

Sell -
Mergr

Product

Company

Legal